Overview

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxi

Status:
Completed

Trial end date:
2019-01-09

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the noninferiority of switching to emtricitabine/rilpivirine /tenofovir alafenamide (FTC/RPV/TAF) fixed-dose combination (FDC) as compared to continuing FTC/RPV/tenofovir disoproxil fumarate (TDF) FDC (FTC/RPV/TDF) in virologically suppressed HIV-1 infected participants.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Emtricitabine
Emtricitabine, Rilpivirine, Tenofovir Drug Combination
Rilpivirine
Tenofovir